WASHINGTON - Abbott Laboratories said Friday it will withdraw its diet pill Meridia in the U.S.
PHOENIX - An Arizona man who lost his eligibility for a state-funded transplant due to state budget cuts learned Wednesday he is the beneficiary of an anonymous donation to pay for the life-saving procedure.
PHOENIX - A Phoenix man awaiting a bone-marrow transplant got good news Friday - word of two donors who are possible matches.
U.S. health regulators dealt a major blow to the controversial diabetes pill Avandia Thursday, requiring doctors and patients to sign consent forms before starting a prescription of the drug.
European regulators ordered the diabetes drug Avandia off the market and the Food and Drug Administration placed stringent restrictions on its use in the United States, saying heart attack risks associated with the former blockbuster are too great a safety concern to continue its use for most people.
- FDA restricts use of controversial diabetes pill
- FDA panel split on withdrawing diet pill Meridia
- FDA questions safety, effectiveness with diet pill
- FDA mulls pulling diet pill linked to heart attack
- Picking right blood pressure medicine challenging
- Journal editors question sale of diet pill Meridia
- Diabetes now tops Vietnam vets' claims
- Report: Cancer is the world's costliest disease
- Genzyme, Isis say cholesterol drug meets goals
- FDA issues hold on much-debated Avandia study
- Experimental diet pill shows promise, little risk
- FDA panel: Diabetes drug should stay on market
- Diabetes pill controversy shows rift in FDA ranks
- FDA review spotlights heart risk of diabetes pill
- European agency to review safety of GSK's Avandia
- Pfizer gets EU approval for kids' cholesterol drug
- Risky drugs pulled from the market in recent years
- When is a drug too risky to stay on the market?
- Cholesterol drugs for the healthy still debatable
- Diabetes drug risks reported ahead of FDA hearing
- Blood pressure pills could raise cancer risk
- GE invests in $5M in heart disease test maker
- Merck settles patent dispute on cholesterol drug
- Study finds possible heart risk with prostate drug
- US seeks more detail on Astra cholesterol drug
- FDA questions new use for Boston Science device
- Arteries improve after smokers quit, study finds
- Many WTC responders show early signs of heart woes
- Analyst: Merck's Vytorin sales will keep dropping
- Australian court: Vioxx doubled heart attack risk
- Scientists try to break fat-and-disease link
- Merck: Last Vioxx patient payouts to be made soon
- Hot tip: Target inflammation to ease obesity ills
- Glaxo defends handling of Avandia heart risks
- FDA warns of heart risk with HIV drug combination